Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

Overexpression of c-Met protein and epidermal growth factor receptor (EGFR) mutations can co-occur in non–small-cell lung cancer (NSCLC), providing strong rationale for dual targeting. Telisotuzumab vedotin (Teliso-V), a first-in-class antibody-drug conjugate targeting c-Met, has shown a tolerable s...

Descripción completa

Detalles Bibliográficos
Autores principales: Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Spira, Alex, Angevin, Eric, Su, Wu-Chou, Hong, David S., Strickler, John H., Motwani, Monica, Dunbar, Martin, Parikh, Apurvasena, Noon, Elysa, Blot, Vincent, Wu, Jun, Kelly, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928626/
https://www.ncbi.nlm.nih.gov/pubmed/36288547
http://dx.doi.org/10.1200/JCO.22.00739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9928626/
https://www.ncbi.nlm.nih.gov/pubmed/36288547
http://dx.doi.org/10.1200/JCO.22.00739

Ejemplares similares